Janux Therapeutics (NASDAQ:JANX) Stock Price Down 6.8% on Insider Selling

Janux Therapeutics, Inc. (NASDAQ:JANX)’s share price traded down 6.8% on Wednesday after an insider sold shares in the company. The stock traded as low as $53.90 and last traded at $53.90. 201,332 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 983,251 shares. The stock had previously closed at $57.81.

Specifically, CEO David Alan Campbell sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the transaction, the chief executive officer now directly owns 293,054 shares in the company, valued at $17,583,240. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Ratings Changes

Several analysts recently commented on the company. Stifel Nicolaus boosted their price target on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday. Scotiabank boosted their target price on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research report on Wednesday, December 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Finally, Leerink Partners boosted their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Stock Performance

The company has a market cap of $2.45 billion, a P/E ratio of -39.97 and a beta of 3.23. The firm’s 50 day moving average price is $54.42 and its two-hundred day moving average price is $48.18.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. The company’s revenue for the quarter was down 82.6% on a year-over-year basis. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Trading of Janux Therapeutics

Institutional investors have recently modified their holdings of the business. FMR LLC boosted its position in shares of Janux Therapeutics by 0.6% in the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after acquiring an additional 47,075 shares during the period. Janus Henderson Group PLC grew its position in shares of Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after purchasing an additional 721,563 shares in the last quarter. Logos Global Management LP increased its holdings in shares of Janux Therapeutics by 400.0% in the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after purchasing an additional 600,000 shares during the period. Geode Capital Management LLC raised its position in shares of Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after buying an additional 38,490 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Janux Therapeutics by 190.2% during the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after buying an additional 259,445 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.